CoChat

Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope

Giugliano, Dario, Meier, Juris J., Esposito, Katherine · 2019 · Diabetes, Obesity and Metabolism
Cited by 52

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

An excess risk of heart failure (HF) persists in patients with type 2 diabetes (T2D) despite optimal control of an array of conventional risk factors, including hyperglycaemia. Twelve cardiovascular outcome trials (CVOTs) have been published to date, although none, with the exception of the DECLARE trial with dapagliflozin, has included HF as a primary endpoint. The four trials with dipeptidyl‐peptidase inhibitors (DPP‐4i) (SAVOR‐TIMI 53 with saxagliptin, EXAMINE with alogliptin, TECOS with sitagliptin and CARMELINA with linagliptin) failed to show any significant effect on HF risk in patients with T2D, with the notable exception of saxagliptin which was associated with a 27% increased risk. Five completed CVOTs with the GLP‐1 RAs lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN‐6), exenatide once weekly (EXSCEL) and albiglutide (HARMONY) also failed to reveal any significant effect on HF risk. The three trials with sodium glucose co‐transporter‐2 inhibitors (SGLT‐2i) (EMPA‐REG OUTCOME with empagliflozin, CANVAS with canagliflozin and DECLARE with dapagliflozin) all revealed a robust and significant reduction in the hazard ratios of hospitalization for HF, from 27% to 35%, which remained consistent, significant and of similar magnitude regardless of the presence of a history of HF or established atherosclerotic cardiovascular disease. There is no association between reductions in HF risk and haemoglobin A1c (A1C) levels, while there is a significant association between reductions in HR for MACE and A1C levels (Spearman's correlation, r = 0.695; P = 0.013). All of the 12 CVOTs completed to date have provided reassurance of the overall cardiovascular safety of the newer anti‐hyperglycaemic drugs. At present, the robust, consistent and reproducible reduction of approximately 30% in the risk of HF with SGLT‐2i may be considered a class effect. The beneficial effect on MACE outcome observed with the use of some GLP‐1RAs and SGLT‐2i must be interpreted within the frame of the single trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13629

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 16

  1. Willey CJ, 2006, Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control, Am J Manag Care, 12, 435
  2. 10.1007/s12020-017-1517-9 · DOI
  3. 10.1111/j.1600-051X.1988.tb01003.x · DOI · Paper page
  4. 10.1056/NEJMoa0802743 · DOI · Paper page
  5. 10.1056/NEJMoa0802987 · DOI · Paper page
  6. 10.1056/NEJMoa0806470 · DOI · Paper page
  7. 10.1161/CIRCULATIONAHA.116.022194 · DOI · Paper page
  8. 10.1111/dom.13492 · DOI
  9. 10.2337/dc18-0831 · DOI · Paper page
  10. Rosenstock J, 2018, Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial, JAMA
  11. 10.1056/NEJMoa1612917 · DOI · Paper page
  12. 10.1056/NEJMoa1611925 · DOI · Paper page
  13. 10.1161/CIRCULATIONAHA.118.034222 · DOI · Paper page
  14. Fitchett D, 2017, Empagliflozin (EMPA) reduces heart failure irrespective of control of blood pressure (BP), low density lipoprotein cholesterol (LDL‐C), and HbA1c, Diabetes, 66, A312
  15. 10.2337/db17-0100 · DOI · Paper page
  16. Furberg CD, 2000, Class effects and evidence based medicine, Clin Cardiol, 23, 15, 10.1002/clc.4960230705 · DOI

Cited by

See all 52

Metadata

Authors
Giugliano, D., Meier, J. J., & Esposito, K.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2019-02-14
Volume
21
Issue
5
Pages
1081-1087
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2908065012
Cited by
52
References
26
FWCI
7.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. https://app.cochat.ai/papers/10.1111/dom.13629
The paper
Giugliano, D., Meier, J. J., & Esposito, K. (2019). Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13629

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.